Table 2.
Use of selected reproductive health preventive screening and unadjusted prevalence ratios, by source of OCs
| Outcome (sample included)a |
US clinic (%) |
OTC from Mexico (%) |
Prevalence ratio |
χ2
p value |
|---|---|---|---|---|
| Pap smear within last 3 years (age 21–44; n=822)b |
99.3 | 90.8 | 1.09 | <.001 |
| Ever had a pelvic examination (age 18–44; n=1,018) |
93.6 | 88.5 | 1.06 | .004 |
| Ever had a clinical breast examination (age 40–44; n=120) |
100.0 | 88.9 | 1.12 | .030 |
| Ever been screened for STIs (age 18–24; n=292) |
86.6 | 71.7 | 1.21 | .002 |
a
Sample included reflects age range for current clinical recommendations, bounded by the age range of our sample (18 to 44 years).
b
Pap smear within the last 3 years measured at the final interview; all others measured at baseline.